Dublin, Jan. 17, 2018 -- The "Diagnostic and Guided Interventional Cardiology Products Market" report has been added to ResearchAndMarkets.com's offering.
Global product sales are projected to expand at a compound annual growth rate (CAGR) of 6.4% during 2016-21, increasing from approximately $3,491.3m in 2016 to an estimated $4,761.4m in 2021.
The global market for diagnostic and guided interventional cardiology products is being driven by the increasing burden of cardiovascular disease (CVD). CVD is the leading cause of death globally, responsible for over 17 million deaths annually. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global diagnostic and guided interventional cardiology products market, which includes transcatheter angiography, guidewire-based intravascular stenosis assessment, intracardiac echocardiography (ICE), intravascular ultrasound (IVUS), optical coherence tomography (OCT), and robotic-assisted surgical systems.
This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for diagnostic and guided interventional cardiology products.
Report Highlights:
- Diagnostic interventional cardiology products are being utilized less frequently in the preoperative work-up of patients with suspected cardiovascular disease. These technologies are primarily utilized to guide minimally invasive therapies (eg stenting).
- Angiography devices, including cardiac X-ray systems and transcatheter devices, accounted for 59% of total product sales in 2016. Sales of ICE and OCT systems are expected to experience the strongest growth throughout the forecast period (2016-21).
- The market for diagnostic and guided interventional cardiology devices is anticipated to experience moderate growth during the forecast period, increasing to an estimated $4.8bn by 2021.
- The increasing burden of cardiovascular diseases (CVDs) and the growing elderly demographic, a high risk demographic for the development of CVDs, are the main factors driving growth in product sales.
- The US market for diagnostic and guided interventional cardiology devices accounted for approximately 35% of all sales, followed by the five major European markets (France, Germany, Italy, Spain, and the UK). The strongest growth in biopsy product sales is expected to occur in the Rest of the World segment, which is being driven by demand for more sophisticated healthcare services in emerging markets.
Key Topics Covered:
Executive Summary
i. Cardiovascular diseases overview
ii. Global diagnostic and guided interventional cardiology products market
a. Selected market drivers and limiters
b. Device segment insights
c. Technology trends
iii. Methodology
1. Cardiovascular Diseases Overview
1.1 Acute coronary syndrome
1.1.1 Atherosclerosis
1.1.2 Angina pectoris
1.1.3 Myocardial infarction
1.2 Hypertension
1.3 Cardiomyopathy
1.4 Congenital heart defects
1.5 Heart failure
1.6 Peripheral vascular disease
1.7 Cerebrovascular disease
1.8 Bibliography
2. Diagnostic and Guided Interventional Cardiology Products
2.1 Angiography
2.1.1 Angiography catheters
2.1.2 Angiography guidewires
2.1.3 Cardiovascular X-ray systems
2.2 Fractional flow reserve
2.3 Intracardiac echocardiography
2.4 Intravascular ultrasound
2.5 Optical coherence tomography
2.6 Robotic-assisted systems
2.7 Bibliography
3. Diagnostic and Guided Interventional Cardiology Products Market
3.1 Global competitors
3.2 Market forecast: US
3.3 Market forecast: five major EU markets
3.4 Market forecast: Japan
3.5 Market forecast: RoW
3.6 Bibliography
For more information about this report visit https://www.researchandmarkets.com/research/t3hffs/global_diagnostic?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, Cardiovascular Devices, Cardiology


Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



